HRP20171031T1 - Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze - Google Patents

Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze Download PDF

Info

Publication number
HRP20171031T1
HRP20171031T1 HRP20171031TT HRP20171031T HRP20171031T1 HR P20171031 T1 HRP20171031 T1 HR P20171031T1 HR P20171031T T HRP20171031T T HR P20171031TT HR P20171031 T HRP20171031 T HR P20171031T HR P20171031 T1 HRP20171031 T1 HR P20171031T1
Authority
HR
Croatia
Prior art keywords
carbazole
dioxo
carboxamide
fluoro
chloro
Prior art date
Application number
HRP20171031TT
Other languages
English (en)
Croatian (hr)
Inventor
Joseph A. Tino
Anurag S. Srivastava
Soo Sung Ko
Michael Galella
Charles M. Langevine
George V. Delucca
Qingjie Liu
Douglas G. Batt
Scott Hunter Watterson
Qing Shi
Myra Beaudoin BERTRAND
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20171031T1 publication Critical patent/HRP20171031T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
HRP20171031TT 2013-06-25 2014-06-25 Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze HRP20171031T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839141P 2013-06-25 2013-06-25
PCT/US2014/043978 WO2014210085A1 (en) 2013-06-25 2014-06-25 Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
EP14740094.9A EP3013814B1 (en) 2013-06-25 2014-06-25 Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20171031T1 true HRP20171031T1 (hr) 2017-10-06

Family

ID=51210830

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171031TT HRP20171031T1 (hr) 2013-06-25 2014-06-25 Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze

Country Status (31)

Country Link
US (6) US9334290B2 (en:Method)
EP (1) EP3013814B1 (en:Method)
JP (1) JP6353529B2 (en:Method)
KR (1) KR102346508B1 (en:Method)
CN (1) CN105358546B (en:Method)
AR (1) AR096721A1 (en:Method)
AU (1) AU2014302548B2 (en:Method)
BR (1) BR112015030723A8 (en:Method)
CA (1) CA2916500A1 (en:Method)
CL (1) CL2015003635A1 (en:Method)
CY (1) CY1119371T1 (en:Method)
DK (1) DK3013814T3 (en:Method)
EA (1) EA026729B1 (en:Method)
ES (1) ES2636652T3 (en:Method)
HR (1) HRP20171031T1 (en:Method)
HU (1) HUE034460T2 (en:Method)
IL (1) IL243296B (en:Method)
LT (1) LT3013814T (en:Method)
MA (1) MA38648B1 (en:Method)
MY (1) MY176631A (en:Method)
PE (1) PE20160519A1 (en:Method)
PH (1) PH12015502630A1 (en:Method)
PL (1) PL3013814T3 (en:Method)
PT (1) PT3013814T (en:Method)
RS (1) RS56371B1 (en:Method)
SI (1) SI3013814T1 (en:Method)
SM (1) SMT201700422T1 (en:Method)
TN (1) TN2015000529A1 (en:Method)
TW (1) TWI648272B (en:Method)
UY (1) UY35625A (en:Method)
WO (1) WO2014210085A1 (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014210087A1 (en) 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
LT3209651T (lt) * 2014-10-24 2020-01-10 Bristol-Myers Squibb Company Karbazolo dariniai
JP6592512B2 (ja) 2014-10-24 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式アトロプ異性体の化合物
LT3461821T (lt) 2014-10-24 2020-08-10 Bristol-Myers Squibb Company Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai
US10842963B2 (en) 2016-07-01 2020-11-24 Brio Device, LLC Intubation stylet with video feed
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
US10875843B2 (en) 2016-12-20 2020-12-29 Bristol-Myers Squibb Company Process for preparing tetrahydrocarbazole carboxamide compound
EP3789040A4 (en) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
AU2023220628A1 (en) * 2022-02-15 2024-05-23 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2587192A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
US7947835B2 (en) 2005-03-10 2011-05-24 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
JP2009508872A (ja) 2005-09-16 2009-03-05 セレネックス， インコーポレイテッド カルバゾール誘導体
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8518964B2 (en) 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
EP2231143B1 (en) 2007-12-13 2013-07-03 Merck Sharp & Dohme Corp. 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES
FI2247558T4 (fi) 2008-02-14 2024-09-19 Lilly Co Eli Uusia kuvantamisaineita neurologisen toimintahäiriön toteamiseen
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
EP2391602B1 (en) * 2008-12-19 2013-12-04 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
US9029387B2 (en) 2010-03-26 2015-05-12 Merck Patent Gmbh Benzonaphthyridinamines as autotaxin inhibitors
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy

Also Published As

Publication number Publication date
UY35625A (es) 2014-12-31
US9334290B2 (en) 2016-05-10
TW201536774A (zh) 2015-10-01
EA026729B1 (ru) 2017-05-31
BR112015030723A8 (pt) 2020-01-07
AU2014302548A1 (en) 2016-02-11
PE20160519A1 (es) 2016-05-21
PT3013814T (pt) 2017-08-10
US20170283438A1 (en) 2017-10-05
CN105358546A (zh) 2016-02-24
RS56371B1 (sr) 2017-12-29
US10106559B2 (en) 2018-10-23
CY1119371T1 (el) 2018-02-14
MA38648A1 (fr) 2017-09-29
ES2636652T3 (es) 2017-10-06
AR096721A1 (es) 2016-01-27
US20190023719A1 (en) 2019-01-24
US20160194338A1 (en) 2016-07-07
SMT201700422T1 (it) 2017-11-15
MA38648B1 (fr) 2018-06-29
TWI648272B (zh) 2019-01-21
US20180079758A1 (en) 2018-03-22
US9850258B2 (en) 2017-12-26
BR112015030723A2 (pt) 2017-07-25
CN105358546B (zh) 2017-10-31
US20140378475A1 (en) 2014-12-25
WO2014210085A1 (en) 2014-12-31
EP3013814B1 (en) 2017-06-14
SI3013814T1 (sl) 2017-08-31
MY176631A (en) 2020-08-19
WO2014210085A9 (en) 2015-12-23
CA2916500A1 (en) 2014-12-31
TN2015000529A1 (en) 2017-04-06
JP6353529B2 (ja) 2018-07-04
KR20160022889A (ko) 2016-03-02
KR102346508B1 (ko) 2022-01-03
HUE034460T2 (en) 2018-02-28
US20190382416A1 (en) 2019-12-19
PH12015502630A1 (en) 2016-03-07
EA201592287A1 (ru) 2016-06-30
AU2014302548B2 (en) 2018-05-10
JP2016523907A (ja) 2016-08-12
IL243296B (en) 2018-05-31
EP3013814A1 (en) 2016-05-04
US10435415B2 (en) 2019-10-08
CL2015003635A1 (es) 2016-07-29
HK1223359A1 (en) 2017-07-28
PL3013814T3 (pl) 2017-11-30
DK3013814T3 (en) 2017-09-25
LT3013814T (lt) 2017-08-10

Similar Documents

Publication Publication Date Title
HRP20171031T1 (hr) Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
SI3074386T1 (en) New aminopyrimidine derivatives
JP2019509276A5 (en:Method)
HRP20231048T1 (hr) Derivati bipirazola kao jak inhibitori
JP2016506962A5 (en:Method)
JP2016506960A5 (en:Method)
HRP20170112T1 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2016523907A5 (en:Method)
SI3008053T1 (en) PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
PE20140245A1 (es) Compuesto de furo[3,2-d]pirimidina
JP2013523710A5 (en:Method)
JP2015503609A5 (en:Method)
HRP20210447T1 (hr) Piridinski spoj
HRP20171453T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
JP2014513110A5 (en:Method)
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
HRP20150427T1 (hr) Ne-nukleozidni inhibitori reverzne transkriptaze
JP2018515525A5 (en:Method)
AR116880A1 (es) Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака